Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Telemedicine Self-examination of Speech and Memory for Rapid Detection of Cognitive Impairments Using Machine Learning Methods

27. april 2026 opdateret af: Marie Kompasová, Faculty Hospital Kralovske Vinohrady
Early cognitive disorders diagnosis is becoming increasingly important due to population aging. The most common causes include Alzheimer's disease and frontotemporal dementia. These diseases are also manifested by changes in speech. NLP allows us to identify and classify these changes. The project aims to develop a web application for self-assessment and automated detection of cognitive disorders from speech. The application will have a form of a dialogue system using machine learning methods. The novelty of this approach is the possibility of an efficient self-assessment of a wide spectrum of the Czech population from their homes and an automated evaluation of test results. Early detection can be followed by a more detailed diagnosis and adequate treatment.

Studieoversigt

Status

Tilmelding efter invitation

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

500

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Tjekkiet
      • Pilsen, Tjekkiet, 306 14
        • Západočeská univerzita v Plzni / Fakulta aplikovaných věd
      • Prague, Tjekkiet, 100 00
        • Faculty Hospital Kralovske Vinohrady
      • Prague, Tjekkiet
        • Fyzikální ústav AV ČR, v. v. i.

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria for the group of healthy participants:

  • age over 45 years
  • Czech as the native language
  • must meet the criteria in a questionnaire with questions focused on a history of brain injury or psychiatric history or medication use
  • must achieve normal scores on questionnaires assessing mood

Inclusion Criteria for the group of patients:

- be diagnosed with mild neurocognitive impairment (MCI) or neurocognitive disorder (dementia) according to the international DSM-5 criteria

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Diagnostisk
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Group of patients with neurocognitive disorder
The experimental group consists of patients with Mild Cognitive Impariment (MCI) and dementia.
Diagnostisk test: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
A brief individually administered battery to measure cognitive decline or improvement across five domains in ages 12 to 89 years 11 months.
Diagnostisk test: the Mississippi Aphasia Screening Test
he Mississippi Aphasia Screening Test (MAST) was developed as a brief, repeatable screening measure for individuals with severely impaired communication/language skills.
Diagnostisk test: Amnesia Light and Brief Assessment (ALBA)
Very brief test used to measure deficits of more cognitive functions (short-term, episodic, semantic amnesia, sensory and motor aphasia, apraxia, psychomotor speed).
Diagnostisk test: The Picture naming and immediate recall test (PICNIR)
Very brief test used to measure deficits of more cognitive functions (short-term, episodic, semantic amnesia, sensory and motor aphasia, apraxia, psychomotor speed).
Diagnostisk test: Geriatric Depression Scale (GDS-15)
The Geriatric Depression Scale (GDS-15), used to screen for depression in adults aged 55 and older, consists of 15 items that assess mental health based on feelings over the past week.
Diagnostisk test: The Beck Anxiety Inventory (BAI)
A formative assessment and rating scale of anxiety.
Diagnostisk test: Digitial Diagnostics of Dementia (DDD)
Our experimental screening battery developed for this study.
Aktiv komparator: Healthy elderly participants
The control group consists of cognitively healthy elderly participants.
Diagnostisk test: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
A brief individually administered battery to measure cognitive decline or improvement across five domains in ages 12 to 89 years 11 months.
Diagnostisk test: the Mississippi Aphasia Screening Test
he Mississippi Aphasia Screening Test (MAST) was developed as a brief, repeatable screening measure for individuals with severely impaired communication/language skills.
Diagnostisk test: Amnesia Light and Brief Assessment (ALBA)
Very brief test used to measure deficits of more cognitive functions (short-term, episodic, semantic amnesia, sensory and motor aphasia, apraxia, psychomotor speed).
Diagnostisk test: The Picture naming and immediate recall test (PICNIR)
Very brief test used to measure deficits of more cognitive functions (short-term, episodic, semantic amnesia, sensory and motor aphasia, apraxia, psychomotor speed).
Diagnostisk test: Geriatric Depression Scale (GDS-15)
The Geriatric Depression Scale (GDS-15), used to screen for depression in adults aged 55 and older, consists of 15 items that assess mental health based on feelings over the past week.
Diagnostisk test: The Beck Anxiety Inventory (BAI)
A formative assessment and rating scale of anxiety.
Diagnostisk test: Digitial Diagnostics of Dementia (DDD)
Our experimental screening battery developed for this study.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
The difference in results between groups of patients with cognitive impairment and healthy individuals in individual parts of our experimental neuropsychological battery Diagnostic Test: Digitial Diagnostics of Dementia (DDD)
Tidsramme: Through study completion, an average of 2 years
Through study completion, an average of 2 years
Correlation of the results of our experimental battery (DDD) with RBANS
Tidsramme: Through study completion, an average of 2 years
Through study completion, an average of 2 years
Correlation of the results of our experimental battery (DDD) with MAST
Tidsramme: Through study completion, an average of 2 years
Through study completion, an average of 2 years
Correlation of the results of our experimental battery (DDD) with ALBA
Tidsramme: Through study completion, an average of 2 years
Through study completion, an average of 2 years
Correlation of the results of our experimental battery (DDD) with POBAV
Tidsramme: Through study completion, an average of 2 years
Through study completion, an average of 2 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Faculty Hospital Kralovske Vinohrady

Efterforskere

  • Studiestol: Luboš Šmídl, Ing. Ph.D., Západočeská univerzita v Plzni / Fakulta aplikovaných věd
  • Ledende efterforsker: Jan Švec, Ing. Ph.D., Západočeská univerzita v Plzni / Fakulta aplikovaných věd
  • Ledende efterforsker: Filip Polák, Ing., Západočeská univerzita v Plzni / Fakulta aplikovaných věd
  • Studieleder: Aleš Bartoš, prof. MUDr. Ph.D., Fakultni nemocnice Kralovske Vinohrady
  • Studieleder: Martin Víta, Mgr. Ph.D., Fyzikální ústav AV ČR, v. v. i.
  • Ledende efterforsker: Marie Kompasová, Mgr., Univerzita Karlova, Fakultní nemocnice Královské Vinohrady
  • Ledende efterforsker: Michaela Zapletalová, Mgr., Univerzita Palackého, Fakultní nemocnice Královské Vinohrady

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. september 2023

Primær færdiggørelse (Faktiske)

31. december 2025

Studieafslutning (Anslået)

31. august 2026

Datoer for studieregistrering

Først indsendt

16. december 2025

Først indsendt, der opfyldte QC-kriterier

27. april 2026

Først opslået (Faktiske)

30. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. april 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. april 2026

Sidst verificeret

1. april 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • TQ01000332 (Andet bevillings-/finansieringsnummer: Technology Agency of the Czech Republic)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner